SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT02282267

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Blood Detection of EGFR Mutation For Iressa Treatment

This study was proposed to validate the efficacy of gefitinib as first-line therapy in advanced lung adenocarcinoma with EGFR mutation determined by plasma cf-DNA.

NCT02282267 Lung Adenocarcinoma
MeSH:Adenocarcinoma Adenocarcinoma of Lung

1 Interventions

Name: Gefitinib

Description: Iressa 250mg oral daily
Type: Drug
Group Labels: 1


Primary Outcomes

Measure: objective response rate of gefitinib

Time: up to 6 months

Purpose: Treatment

Allocation: N/A

Single Group Assignment

There are 2 SNPs


1 L858R

- EGFR sensitive mutation (including exon 19 del and/or exon 21 L858R) in plasma cf-DNA by ddPCR. --- L858R ---

2 T790M

Meanwhile, this study was also proposed to explore the best intervention time of anti-resistant drugs (such as AZD 9291, a T790M inhibitor) through the quantitative and dynamic analysis of EGFR sensitive and resistant mutation in plasma cf-DNA during EGFR-TKI treatment process. --- T790M ---

HPO Nodes